pentoxifylline has been researched along with Obesity in 10 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline is in clinical trials for non-alcoholic fatty liver disease and diabetic nephropathy." | 7.78 | Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. ( Bado, A; Eliat, PA; Fautrel, A; Fromenty, B; Lettéron, P; Massart, J; Noury, F; Robin, MA, 2012) |
| "Cardiac inflammation was interrogated via expression levels of TNF α, interleukins 6 and 10, phosphorylated STAT4 and lipoxygenases 12 and 12/15." | 5.62 | Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. ( Abdelzaher, LA; Ali, M; Bakr, MH; Desai, AA; Mali, V; Radwan, E; Sayed, SA, 2021) |
| "Pentoxifylline is in clinical trials for non-alcoholic fatty liver disease and diabetic nephropathy." | 3.78 | Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. ( Bado, A; Eliat, PA; Fautrel, A; Fromenty, B; Lettéron, P; Massart, J; Noury, F; Robin, MA, 2012) |
| "Cardiac inflammation was interrogated via expression levels of TNF α, interleukins 6 and 10, phosphorylated STAT4 and lipoxygenases 12 and 12/15." | 1.62 | Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. ( Abdelzaher, LA; Ali, M; Bakr, MH; Desai, AA; Mali, V; Radwan, E; Sayed, SA, 2021) |
| "Central obesity is associated with low-grade inflammation that promotes type 2 diabetes and cardiovascular disease in obese individuals." | 1.37 | Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. ( Bevard, MH; Chakrabarti, SK; Cole, BK; Dobrian, AD; Gu, J; Keller, SR; Ma, Q; Nadler, JL; Pei, H; Vandenhoff, GE; Wen, Y; Williams, MD, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, M | 1 |
| Bakr, MH | 1 |
| Abdelzaher, LA | 1 |
| Sayed, SA | 1 |
| Mali, V | 1 |
| Desai, AA | 1 |
| Radwan, E | 1 |
| Matlock, SM | 1 |
| Rush, JL | 1 |
| Afzal, W | 1 |
| Fulton, EH | 1 |
| Berney, SM | 1 |
| Wong, HK | 1 |
| Shirakami, Y | 1 |
| Shimizu, M | 1 |
| Kubota, M | 1 |
| Ohno, T | 1 |
| Kochi, T | 1 |
| Nakamura, N | 1 |
| Sumi, T | 1 |
| Tanaka, T | 1 |
| Moriwaki, H | 1 |
| Seishima, M | 1 |
| Chakrabarti, SK | 1 |
| Wen, Y | 1 |
| Dobrian, AD | 1 |
| Cole, BK | 1 |
| Ma, Q | 1 |
| Pei, H | 1 |
| Williams, MD | 1 |
| Bevard, MH | 1 |
| Vandenhoff, GE | 1 |
| Keller, SR | 1 |
| Gu, J | 1 |
| Nadler, JL | 1 |
| Massart, J | 1 |
| Robin, MA | 1 |
| Noury, F | 1 |
| Fautrel, A | 1 |
| Lettéron, P | 1 |
| Bado, A | 1 |
| Eliat, PA | 1 |
| Fromenty, B | 1 |
| Muldowney, JA | 1 |
| Chen, Q | 1 |
| Blakemore, DL | 1 |
| Vaughan, DE | 1 |
| Cigolini, M | 1 |
| Tonoli, M | 1 |
| Borgato, L | 1 |
| Frigotto, L | 1 |
| Manzato, F | 1 |
| Zeminian, S | 1 |
| Cardinale, C | 1 |
| Camin, M | 1 |
| Chiaramonte, E | 1 |
| De Sandre, G | 1 |
| Lunardi, C | 1 |
| McCarty, MF | 1 |
| Dembowski, U | 1 |
| Marx-Heep, I | 1 |
| Adams, HJ | 1 |
| Bittiner, SB | 1 |
1 trial available for pentoxifylline and Obesity
| Article | Year |
|---|---|
Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: a pilot study.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Follow-Up Stud | 2012 |
9 other studies available for pentoxifylline and Obesity
| Article | Year |
|---|---|
Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Apoptosis; Blood Glucose; Body Weight; Disea | 2021 |
Spontaneous ulcerations of the breast.
Topics: Angiomatosis; Breast; Breast Diseases; Female; Humans; Middle Aged; Obesity; Pentoxifylline; Phospho | 2020 |
Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis.
Topics: Animals; Diabetes Mellitus, Experimental; Inflammation; Lipogenesis; Liver Neoplasms, Experimental; | 2016 |
Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats.
Topics: 3T3-L1 Cells; 5-Lipoxygenase-Activating Proteins; Animals; Anti-Inflammatory Agents, Non-Steroidal; | 2011 |
Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis.
Topics: Adipocytes; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers; Blood | 2012 |
Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?
Topics: Adipose Tissue; Blotting, Northern; Culture Techniques; Dose-Response Relationship, Drug; Enzyme-Lin | 1999 |
Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline.
Topics: Alcohol Drinking; Animals; Cardiovascular Diseases; Diabetes Mellitus; Fatty Acids, Essential; Human | 1999 |
[Angioneuropathies, angiolopathies and other disorders of blood circulation. Treatment in ambulatory patients].
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Obes | 1979 |
Oxpentifylline treatment of venous leg ulcers.
Topics: Humans; Leg Ulcer; Obesity; Pentoxifylline; Theobromine | 1990 |